Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt Past Earnings Performance

Past criteria checks 5/6

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt has been growing earnings at an average annual rate of 25.4%, while the Pharmaceuticals industry saw earnings declining at 0.3% annually. Revenues have been growing at an average rate of 12.4% per year. Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt's return on equity is 19.6%, and it has net margins of 28.2%.

Key information

25.4%

Earnings growth rate

25.6%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	12.4%
Return on equity	19.6%
Net Margin	28.2%
Next Earnings Update	12 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:RGED.F Revenue, expenses and earnings (HUF Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Jun 24	811,415	229,129	203,363	84,358
31 Mar 24	798,937	187,874	199,584	83,924
31 Dec 23	805,158	158,850	196,619	78,344
30 Sep 23	825,948	95,563	201,667	78,574
30 Jun 23	855,211	123,426	199,704	77,387
31 Mar 23	844,351	157,720	191,469	75,290
31 Dec 22	802,755	169,076	182,350	75,109
30 Sep 22	755,061	242,521	165,816	68,730
30 Jun 22	694,772	198,297	155,135	66,489
31 Mar 22	657,758	149,792	146,773	62,419
31 Dec 21	630,595	139,626	143,261	61,005
30 Sep 21	604,708	114,689	139,575	59,304
30 Jun 21	584,887	99,067	136,059	56,079
31 Mar 21	566,244	102,570	132,525	54,418
31 Dec 20	566,776	104,683	133,766	53,977
30 Sep 20	555,124	68,482	134,358	55,110
30 Jun 20	544,964	68,130	137,596	53,745
31 Mar 20	527,608	54,123	144,866	52,273
31 Dec 19	507,794	47,135	145,281	48,860
30 Sep 19	490,668	49,451	144,043	46,258
30 Jun 19	462,576	36,071	143,720	43,363
31 Mar 19	453,151	42,857	141,650	40,903
31 Dec 18	445,484	35,348	139,654	40,545
30 Sep 18	434,078	11,939	140,523	41,576
30 Jun 18	441,997	18,899	139,253	40,768
31 Mar 18	445,626	2,997	139,412	41,027
31 Dec 17	444,356	8,885	138,256	39,903
30 Sep 17	439,822	68,291	137,882	37,763
30 Jun 17	429,207	66,829	136,121	36,317
31 Mar 17	413,021	74,992	131,932	35,489
31 Dec 16	389,690	66,200	127,903	35,153
30 Sep 16	372,689	52,016	122,486	32,401
30 Jun 16	368,539	44,525	120,792	33,588
31 Mar 16	366,889	50,419	118,318	33,813
31 Dec 15	365,220	53,863	117,707	34,822
30 Sep 15	366,631	40,482	117,110	40,072
30 Jun 15	362,903	39,300	119,714	42,380
31 Mar 15	353,080	30,652	119,713	42,996
31 Dec 14	353,709	24,950	121,315	43,666
30 Sep 14	355,043	31,723	126,411	43,069
30 Jun 14	348,768	37,367	123,446	42,308
31 Mar 14	354,346	33,058	126,467	41,371
31 Dec 13	351,886	42,766	126,317	40,800

Quality Earnings: RGED.F has high quality earnings.

Growing Profit Margin: RGED.F's current net profit margins (28.2%) are higher than last year (14.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: RGED.F's earnings have grown significantly by 25.4% per year over the past 5 years.

Accelerating Growth: RGED.F's earnings growth over the past year (85.6%) exceeds its 5-year average (25.4% per year).

Earnings vs Industry: RGED.F earnings growth over the past year (85.6%) exceeded the Pharmaceuticals industry 13%.

Return on Equity

High ROE: RGED.F's Return on Equity (19.6%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/10/16 09:23
End of Day Share Price	2024/07/19 00:00
Earnings	2024/06/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt. is covered by 25 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Simon Mather	Barclays
Samuel England	Berenberg
Victoria Lambert	Berenberg